Truist Securities Maintains Buy on Arcellx, Maintains $87 Price Target

Truist Securities analyst Asthika Goonewardene maintains Arcellx with a Buy and maintains $87 price target.

Analyst UpgradesJun 18 13:48 ET

Truist Financial Maintains Arcellx(ACLX.US) With Buy Rating

Truist Financial analyst Asthika Goonewardene maintains $Arcellx(ACLX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 31.7% and a total average return of -4.5% ove

moomoo NewsJun 18 07:34 ET · Ratings

Arcellx(ACLX.US) Officer Sells US$1.1 Million in Common Stock

$Arcellx(ACLX.US)$ Officer Heery Christopher sold 20,000 shares of common stock on Jun 12, 2024 at an average price of $55.1334 for a total value of $1.1 million.Source: Announcement What is statement

moomoo NewsJun 14 17:13 ET

Arcellx Insider Sold Shares Worth $1,102,668, According to a Recent SEC Filing

Christopher Heery, Chief Medical Officer, on June 12, 2024, sold 20,000 shares in Arcellx (ACLX) for $1,102,668. Following the Form 4 filing with the SEC, Heery has control over a total of 9,278 share

MT NewswiresJun 14 16:36 ET

Goldman Cuts 2seventy Bio to Neutral, Cites Competition Concerns

Seeking AlphaJun 6 10:47 ET

Growth Investors: Industry Analysts Just Upgraded Their Arcellx, Inc. (NASDAQ:ACLX) Revenue Forecasts By 14%

Arcellx, Inc. (NASDAQ:ACLX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The revenue forecast for this year has e

Simply Wall StJun 1 08:02 ET